Prostaglandin E2 levels in human brain tumor tissues and arachidonic acid levels in the plasma membrane of human brain tumors

1998 ◽  
Vol 132 (1-2) ◽  
pp. 17-21 ◽  
Author(s):  
E Kökoğlu ◽  
Y Tüter ◽  
K.S Sandıkçı ◽  
Z Yazıcı ◽  
E.Z Ulakoğlu ◽  
...  
Keyword(s):  
Arachidonic Acid ◽  
Plasma Membrane ◽  
Brain Tumor ◽  
Brain Tumors ◽  
Human Brain ◽  
Prostaglandin E2 ◽  
Human Brain Tumor ◽  
Human Brain Tumors ◽  
Tumor Tissues

scholarly journals Automatic Human Brain Tumor Detection in MRI Image Using Template-Based K Means and Improved Fuzzy C Means Clustering Algorithm

2019 ◽  
Vol 3 (2) ◽  
pp. 27 ◽  
Author(s):  
Md Shahariar Alam ◽  
Md Mahbubur Rahman ◽  
Mohammad Amazad Hossain ◽  
Md Khairul Islam ◽  
Kazi Mowdud Ahmed ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Brain Tumors ◽  
Human Brain ◽  
Clustering Algorithm ◽  
Tumor Detection ◽  
Gray Level ◽  
Human Brain Tumor ◽  
Human Brain Tumors ◽  
Fuzzy C Means ◽  
Mri Image

In recent decades, human brain tumor detection has become one of the most challenging issues in medical science. In this paper, we propose a model that includes the template-based K means and improved fuzzy C means (TKFCM) algorithm for detecting human brain tumors in a magnetic resonance imaging (MRI) image. In this proposed algorithm, firstly, the template-based K-means algorithm is used to initialize segmentation significantly through the perfect selection of a template, based on gray-level intensity of image; secondly, the updated membership is determined by the distances from cluster centroid to cluster data points using the fuzzy C-means (FCM) algorithm while it contacts its best result, and finally, the improved FCM clustering algorithm is used for detecting tumor position by updating membership function that is obtained based on the different features of tumor image including Contrast, Energy, Dissimilarity, Homogeneity, Entropy, and Correlation. Simulation results show that the proposed algorithm achieves better detection of abnormal and normal tissues in the human brain under small detachment of gray-level intensity. In addition, this algorithm detects human brain tumors within a very short time—in seconds compared to minutes with other algorithms.

Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors

1994 ◽  
Vol 81 (1) ◽  
pp. 69-77 ◽  
Author(s):  
Takao Nakagawa ◽  
Toshihiko Kubota ◽  
Masanori Kabuto ◽  
Kazufumi Sato ◽  
Hirokazu Kawano ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Matrix Metalloproteinases ◽  
Brain Tumors ◽  
Human Brain ◽  
Tumor Cells ◽  
Tumor Invasion ◽  
Gelatinolytic Activity ◽  
Normal Brain ◽  
Tissue Inhibitor Of Metalloproteinases ◽  
Human Brain Tumor

✓ The role of matrix metalloproteinases (MMP's) and their inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1), in human brain tumor invasion was investigated. Gelatinolytic activity was assayed via gelatin zymography, and four MMP's (MMP-1, MMP-2, MMP-3, and MMP-9) and TIMP-1 were immunolocalized in human brain tumors and in normal brain tissues using monoclonal antibodies. The tissue was surgically removed from 44 patients: glioblastoma (five cases), anaplastic astrocytoma (six cases), astrocytoma (four cases), metastatic tumor (six cases), neurinoma (10 cases), meningioma (10 cases), and normal brain tissue (three cases). Glioblastomas, anaplastic astrocytomas, and metastatic tumors showed high gelatinolytic activity and positive immunostaining for MMP's; TIMP-1 was also expressed in these tumors, but some tumor cells were negative for the antibody. Astrocytomas had low gelatinolytic activity and the tumor cells showed no immunoreactivity for MMP's and TIMP-1. Although neurinomas and meningiomas had only moderate proteinase activity and exhibited positive immunoreactivity for MMP-9, intense expression of TIMP-1 was simultaneously observed in these tumor cells. These findings suggest that MMP's play an important role in human brain tumor invasion, probably due to an imbalance between the production of MMP's and TIMP-1 by the tumor cells.

scholarly journals Expression of CYP1A1 and GSTP1 in Human Brain Tumor Tissues in Pakistan

2013 ◽  
Vol 14 (12) ◽  
pp. 7187-7191 ◽  
Author(s):  
Mussarat Wahid ◽  
Ishrat Mahjabeen ◽  
Ruqia Mehmood Baig ◽  
Mahmood Akhtar Kayani
Keyword(s):  
Brain Tumor ◽  
Human Brain ◽  
Human Brain Tumor ◽  
Tumor Tissues

Cell kinetics studies of human brain tumors by in vitro labeling using anti-BUdR monoclonal antibody

1988 ◽  
Vol 69 (3) ◽  
pp. 371-374 ◽  
Author(s):  
Takafumi Nishizaki ◽  
Tetsuji Orita ◽  
Masahide Saiki ◽  
Yasuhiro Furutani ◽  
Hideo Aoki
Keyword(s):  
Monoclonal Antibody ◽  
Brain Tumors ◽  
Human Brain ◽  
Intravenous Infusion ◽  
Reproductive Age ◽  
Proliferative Potential ◽  
Human Brain Tumor ◽  
Human Brain Tumors

✓ Since the development of a specific monoclonal antibody against the thymidine analogue bromodeoxyuridine (BUdR), many investigators have used intravenous infusion of BUdR to estimate the proliferative potential of human brain tumors. However, side effects such as the induction of cell mutation, latent virus promotion, or inhibition of cytodifferentiation cannot be ignored, and thus many workers hesitate to use it in patients, especially those with hepatic disease or of reproductive age. Furthermore, if BUdR remains in the deoxyribonucleic acid of tumor cells after injection, analysis of the effect of chemical and radiation therapy may not be evaluated correctly. In this report, in vitro BUdR labeling with an anti-BUdR antibody is compared with the in vivo methods described by previous authors. This method appears to be useful for determining the S-phase fraction of human brain tumor. It was more rapid, and was simple, safe, and reproducible as compared to the intravenous infusion method.

The Biological Relevance of Arachidonic Acid Metabolism in Human Brain Tumors

1991 ◽  
pp. 41-48
Author(s):  
Paolo Gaetani ◽  
Chiara Chiabrando ◽  
Marco Danova ◽  
Fulvio Marzatico ◽  
Vittorio Silvani ◽  
...  
Keyword(s):  
Arachidonic Acid ◽  
Brain Tumors ◽  
Human Brain ◽  
Acid Metabolism ◽  
Arachidonic Acid Metabolism ◽  
Human Brain Tumors ◽  
Biological Relevance

The distribution of nuclear DNA from human brain-tumor cells

1978 ◽  
Vol 49 (1) ◽  
pp. 13-21 ◽  
Author(s):  
Takao Hoshino ◽  
Kazuhiro Nomura ◽  
Charles B. Wilson ◽  
Kathy D. Knebel ◽  
Joe W. Gray
Keyword(s):  
Brain Tumor ◽  
Brain Tumors ◽  
Human Brain ◽  
Dna Synthesis ◽  
Tumor Cells ◽  
Malignant Gliomas ◽  
Benign Tumors ◽  
Low Grade ◽  
Human Brain Tumor ◽  
Large Variability

✓ Flow cytometry (FCM) is a technique that measures the quantity of DNA contained in individual nuclei and records a frequency distribution of the DNA content per nucleus in the sampled cell population. Nuclei from a variety of human brain-tumor types were isolated by means of tissue grinding, purified by centrifugation through 40% sucrose (15 minutes at 4000 rpm), fixed with 10% formalin, stained with acriflavin-Feulgen, and analyzed by FCM. Profiles of DNA distribution in histologically benign tumors, such as meningiomas, pituitary adenomas, neuroblastomas, and low-grade astrocytomas, revealed a large diploid population (2C) with a few nuclei in DNA synthesis, as well as a small premitotic population (G2 cells) that contains a 4C DNA complement. In contrast, malignant gliomas, including glioblastomas, consist of more cells in DNA synthesis; these tumor cells show a highly variable distribution of ploidy consisting not only of diploid, and/or aneuploid, but also of triploid, tetraploid, and possibly octaploid populations. Also, a large variability between different regions of each tumor was always observed. In contrast, metastatic brain tumors, despite the fact that they contain a considerable number of cells undergoing DNA synthesis, demonstrate little variability within each individual tumor. The ability to rapidly characterize the cell populations of human brain tumors with FCM may enhance the effectiveness of their clinical management.

scholarly journals Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling

2021 ◽  
Author(s):  
Johanna Schaffenrath ◽  
Tania Wyss ◽  
Liqun He ◽  
Elisabeth Jane Rushing ◽  
Mauro Delorenzi ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Endothelial Cells ◽  
Brain Tumor ◽  
Brain Tumors ◽  
Human Brain ◽  
Blood Brain Barrier ◽  
Tumor Stroma ◽  
Brain Barrier ◽  
Human Brain Tumors ◽  
Blood Brain

Abstract Background Brain tumors, whether primary or secondary, have limited therapeutic options despite advances in understanding driver gene mutations and heterogeneity within tumor cells. The cellular and molecular composition of brain tumor stroma, an important modifier of tumor growth, has been less investigated to date. Only few studies have focused on the vasculature of human brain tumors despite the fact that the blood-brain barrier (BBB) represents the major obstacle for efficient drug delivery. Methods In this study, we employed RNA sequencing to characterize transcriptional alterations of endothelial cells isolated from primary and secondary human brain tumors. We used an immunoprecipitation approach to enrich for endothelial cells from normal brain, glioblastoma (GBM) and lung cancer brain metastasis (BM). Results Analysis of the endothelial transcriptome showed deregulation of genes implicated in cell proliferation, angiogenesis and deposition of extracellular matrix (ECM) in the vasculature of GBM and BM. Deregulation of genes defining the BBB dysfunction module were found in both tumor types. We identified deregulated expression of genes in vessel-associated fibroblasts in GBM. Conclusion We characterize alterations in BBB genes in GBM and BM vasculature and identify proteins that might be exploited for developing drug delivery platforms. In addition, our analysis on vessel-associated fibroblasts in GBM shows that the cellular composition of brain tumor stroma merits further investigation.

Sign in / Sign up

Export Citation Format

Share Document